When it comes to drug prices, what’s dominating the headlines is bad news story after bad news story. Turing Pharmaceuticals raised the price of an old AIDS drug by more than 5,000 percent overnight, and Valeant Pharmaceuticals International raised a blood pressure drug price by nearly 3,000 percent since 2013, among other consumer losing examples. […]
The recent approval of the first biosimilar drug by the FDA will mark the beginning of competition for a class of lifesaving medicines in the U.S., after nearly a decade of availability in Europe and elsewhere. This ConsumerGram will explore how the pending introduction of competition for biologic drugs will lead to immense consumer benefits, both […]
WASHINGTON, Dec. 9, 2014 /PRNewswire-USNewswire/ — The American Consumer Institute Center for Citizen Research (ACI) today hosted an event on Capitol Hill bringing together a panel of experts highlighting the dramatic benefits that unimpeded biosimilars competition would mean for both patients and taxpayers. The event was held as the Food and Drug Administration (FDA) is […]
The Food and Drug Administration (FDA) began approving generic (unbranded) prescription drugs around 30 years ago, and generic drugs are now saving consumers more than one trillion dollars per decade in healthcare costs over their brand named counterparts. Competition from generics has provided more options to doctors and better access to patients – at prices […]
At the 2nd World Congress on Bioavaialability & Bioequivalence 2011- Pharmaceuticals R&D Summit, “Economics of Biosimilars” June 7, 2011.